|814.99||+6.68||+0.83%||Vol 336.64K||1Y Perf 9.30%|
|Oct 4th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||801.83||Analyst Rating||Moderate Buy 1.65|
|Potential %||-1.61||Finscreener Ranking||★★★★ 52.93|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★+ 58.27|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 71.31|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||81.89||Earnings Rating||Strong Buy|
|Market Cap||88.47B||Earnings Date||2nd Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||2nd Nov 2023|
|Estimated EPS Next Report||9.55|
|EPS Growth Next 5 Years %||9.50|
|Avg. Weekly Volume||407.60K|
|Avg. Monthly Volume||396.89K|
|Avg. Quarterly Volume||492.44K|
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock closed at 808.31 per share at the end of the most recent trading day (a -1.19% change compared to the prior day closing price) with a volume of 421.47K shares and market capitalization of 88.47B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 9123 people. Regeneron Pharmaceuticals Inc. CEO is Leonard S. Schleifer.
The one-year performance of Regeneron Pharmaceuticals Inc. stock is 9.3%, while year-to-date (YTD) performance is 12.03%. REGN stock has a five-year performance of 106.18%. Its 52-week range is between 668 and 847.5, which gives REGN stock a 52-week price range ratio of 81.89%
Regeneron Pharmaceuticals Inc. currently has a PE ratio of 15.50, a price-to-book (PB) ratio of 3.74, a price-to-sale (PS) ratio of 8.32, a price to cashflow ratio of 14.70, a PEG ratio of 1.63, a ROA of 22.50%, a ROC of 24.99% and a ROE of 29.79%. The company’s profit margin is 35.87%, its EBITDA margin is 46.70%, and its revenue ttm is $8.76 Billion , which makes it $81.79 revenue per share.
Of the last four earnings reports from Regeneron Pharmaceuticals Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $9.55 for the next earnings report. Regeneron Pharmaceuticals Inc.’s next earnings report date is 02nd Nov 2023.
The consensus rating of Wall Street analysts for Regeneron Pharmaceuticals Inc. is Moderate Buy (1.65), with a target price of $801.83, which is -1.61% compared to the current price. The earnings rating for Regeneron Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Regeneron Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Regeneron Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.74, ATR14 : 13.85, CCI20 : -253.12, Chaikin Money Flow : -0.09, MACD : 2.70, Money Flow Index : 42.43, ROC : -1.83, RSI : 41.63, STOCH (14,3) : 21.00, STOCH RSI : 0.00, UO : 47.51, Williams %R : -79.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Regeneron Pharmaceuticals Inc. in the last 12-months were: Andrew J Murphy (Option Excercise at a value of $1 791 300), Andrew J Murphy (Sold 3 699 shares of value $2 692 066 ), Arthur Frederick Ryan (Sold 439 shares of value $336 484 ), Bonnie L. Bassler (Option Excercise at a value of $944 375), Bonnie L. Bassler (Sold 2 479 shares of value $1 979 501 ), Christopher R. Fenimore (Option Excercise at a value of $1 352 150), Christopher R. Fenimore (Sold 4 036 shares of value $3 148 938 ), Daniel P. Van Plew (Option Excercise at a value of $31 934 280), Daniel P. Van Plew (Sold 19 858 shares of value $14 746 520 ), Fenimore Christopher (Option Excercise at a value of $1 352 150), Fenimore Christopher (Sold 4 036 shares of value $3 148 938 ), George D. Yancopoulos (Sold 16 591 shares of value $13 289 279 ), Goldstein Joseph (Option Excercise at a value of $1 743 922), Goldstein Joseph (Sold 3 613 shares of value $2 890 400 ), Joseph J. Larosa (Option Excercise at a value of $2 704 300), Joseph L. Goldstein (Option Excercise at a value of $1 743 922), Joseph L. Goldstein (Sold 3 613 shares of value $2 890 400 ), Larosa Joseph (Option Excercise at a value of $2 704 300), Marion Mccourt (Option Excercise at a value of $3 203 156), Marion McCourt (Sold 9 364 shares of value $7 065 970 ), Michael S. Brown (Option Excercise at a value of $11 245 057), Michael S. Brown (Sold 22 818 shares of value $17 741 539 ), P. Roy Vagelos (Option Excercise at a value of $11 493 275), Poon Christine (Option Excercise at a value of $3 360 667), Poon Christine (Sold 12 280 shares of value $10 314 827 ), Robert E. Landry (Option Excercise at a value of $6 025 516), Robert E. Landry (Sold 4 251 shares of value $3 336 322 ), Ryan Arthur (Sold 196 shares of value $142 432 ), Stahl Neil (Sold 0 shares of value $-19 983 000 ), Stahl Neil (Sold 11 665 shares of value $9 810 082 ), Vagelos P. (Sold 0 shares of value $-11 493 275 ), Yancopoulos George (Sold 16 591 shares of value $13 289 279 )
Fri, 18 Aug 2023 18:31 GMT RBC says Regeneron news intimates high-dose Eylea approval likely- TipRanks. All rights reserved.
Wed, 09 Aug 2023 19:03 GMT Decibel Therapeutics downgraded to Hold from Buy at JonesResearch- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.